
Cerevel Therapeutics Holdings, Inc.
NASDAQ:CERE
Overview | Financials
Company Name | Cerevel Therapeutics Holdings, Inc. |
Symbol | CERE |
Currency | USD |
Price | 44.96 |
Market Cap | 8,191,487,560 |
Dividend Yield | 0% |
52-week-range | 19.59 - 44.99 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Ronald C. Renaud Jr., M.B.A., MBA |
Website | https://www.cerevel.com |
An error occurred while fetching data.
About Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD